UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75.299

Sortiert nach

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Annals of oncology, 2017-07, Vol.28 (7), p.1569-1575

2017

Volltextzugriff (PDF)

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of oncology, 2017-06, Vol.28 (6), p.1309-1315

2017

Volltextzugriff (PDF)

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Annals of oncology, 2018-03, Vol.29 (3), p.707-714

2018

Volltextzugriff (PDF)

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Annals of oncology, 2019-12, Vol.30 (12), p.2010-2010

2019

Volltextzugriff (PDF)

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of oncology, 2019-11, Vol.30 (11), p.1846-1846

2019

Volltextzugriff (PDF)

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

The New England journal of medicine, 2019-08, Vol.381 (7), p.626-636

2019

Volltextzugriff (PDF)

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

European journal of cancer (1990), 2015-09, Vol.51, p.S709-S710

2015

Volltextzugriff (PDF)

Sustained reduction in seizure frequency with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in children under 6 years of age: Results from the phase 3 EXIST-3 extension phase

European journal of paediatric neurology, 2017-06, Vol.21, p.e33-e33

2017

Volltextzugriff (PDF)

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.181-181

2012

Volltextzugriff (PDF)

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

Annals of oncology, 2007-09, Vol.18 (9), p.1548-1553

2007

Volltextzugriff (PDF)

Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

European journal of cancer (1990), 1996-02, Vol.32 (2), p.243-248

1996

Volltextzugriff (PDF)

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

Annals of oncology, 2005-04, Vol.16 (4), p.597-601

2005

Volltextzugriff (PDF)

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2153-2163

2016

Volltextzugriff (PDF)

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2831-2839

2005

Volltextzugriff (PDF)

Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial

Annals of oncology, 2016-10, Vol.27, p.vi138-vi138

2016

Volltextzugriff (PDF)

Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy–based regimens

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S2-S2-07

2016

Volltextzugriff (PDF)

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin

European journal of cancer (1990), 2004-03, Vol.40 (4), p.563-570

2004

Volltextzugriff (PDF)

PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1578

2017

Volltextzugriff (PDF)

PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1578-S1578

2017

Volltextzugriff (PDF)

Outcomes in patients with tuberous sclerosis complex-associated treatment-refractory seizures, transitioning from placebo in core phase to everolimus during extension phase of the EXIST-3 trial

Journal of the neurological sciences, 2017-10, Vol.381, p.87-87

2017

Volltextzugriff (PDF)

134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

Annals of oncology, 2015-12, Vol.26, p.ix40-ix40

2015

Volltextzugriff (PDF)

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Cancer, 1999-03, Vol.85 (6), p.1261-1268

1999

Volltextzugriff (PDF)

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Annals of oncology, 2019-12, Vol.30 (12), p.2010

2019

Volltextzugriff (PDF)

Interventions to promote physical activity among young and adolescent girls: a systematic review

Health education research, 2011-12, Vol.26 (6), p.1025-1049

2011

Volltextzugriff (PDF)

1 – 25 von 75.299

Suche als RSS-Feed

Aktive Filter

SpracheRussisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27.411)
Mit Volltextzugriff
(23.739)

Publikationsform

9 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(40.665)
Female
(15.215)
Male
(13.289)
Old Medline
(12.479)
Adult
(10.459)
Middle Aged
(8.845)
Aged
(6.030)
Child
(4.895)
Animals
(4.876)
Adolescent
(4.528)
Infant
(2.870)
Child, Preschool
(2.595)
Italy
(2.550)
Dentistry
(2.253)
Infant, Newborn
(2.097)
Pregnancy
(2.051)
Rats
(1.632)
Radiography
(1.252)
Age Factors
(1.212)
Electrocardiography
(1.097)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(50.262)
Jstor Complete Legacy
(12.655)
EZB-FREE-00999 freely available EZB journals
(9.328)
Ingenta.com
(4.314)
Springer Nature - Complete Springer Journals
(4.019)
Publisher or Other Site
(3.056)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.173)
Journals@Ovid Ovid Full Text
(1.872)
IngentaConnect Journals
(1.619)
Elsevier ScienceDirect Journals Complete
(1.203)
Wiley-Blackwell Journals
(644)
Ebook Central Perpetual and DDA
(551)
SAGE Publications
(515)
Wiley Online Library
(431)
Oxford University Press Journals Current
(407)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(356)
APS: American Physical Society E-Journals (Physics)
(332)
eBooks on EBSCOhost
(332)
Cambridge Journals Online (DEFF)
(316)
Peeters Online Journals
(311)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bollettino Della Societa Italiana Di Biologia Sperimentale
(2.719)
Minerva Pediatrica
(2.373)
Minerva Medica
(2.302)
Minerva Chirurgica
(1.615)
Il Foro Italiano
(1.359)
Clinica Terapeutica
(1.208)
Minerva Anestesiologica
(1.196)
Minerva Ginecologica
(1.176)
Revista Medico-Chirurgicala A Societatii De Medici Si Naturalisti Din Iasi
(1.077)
Aevum
(1.044)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(19)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Sustained reduction in seizure frequency with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in children under 6 years of age: Results from the phase 3 EXIST-3 extension phase

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial

Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy–based regimens

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin

PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC

PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC: Topic: Medical Oncology

Outcomes in patients with tuberous sclerosis complex-associated treatment-refractory seizures, transitioning from placebo in core phase to everolimus during extension phase of the EXIST-3 trial

134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Interventions to promote physical activity among young and adolescent girls: a systematic review

Aktive Filter

Suchergebnisse filtern